ALDA Pharmaceuticals Corp.

ALDA Pharmaceuticals Corp.

April 27, 2007 16:24 ET

ALDA Pharmaceuticals Corp.: Insiders Sell Shares to Purchase Options and Private Placement Units

NEW WESTMINSTER, BRITISH COLUMBIA--(CCNMatthews - April 27, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) (the "Company") announces that insiders of the Company have completed the sale of 3,205,825 common shares of ALDA at prices ranging from $0.11 to $0.17 per share through the TSX Venture Exchange. The proceeds obtained through the sale of these shares were used by these insiders to exercise 900,000 options and will also be used to subscribe for Units of the private placement announced on April 4, 2007.

About ALDA Pharmaceuticals Corp.

ALDA's patent-pending T36® therapeutic products contain active ingredients in very low concentrations that act in concert to disrupt the physical structure of all infectious organisms rather than interfering with their metabolic pathways. The competitive advantage is a high degree of effectiveness and safety while preventing microbial resistance, side effects or toxicity. The Company has identified global markets of $10 Billion in its targeted disease areas.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information